Recent deals
A few examples of deals include:
COMMERCIAL
- Research alliance agreement between a Belgian top player in biotech and an international pharmaceutical company.
- Research alliance agreement with a major Belgian university.
- Research, development and commercialization agreement with a Japanese pharmaceutical company.
- Various licensing in / out deals, amongst others with Chinese, Japanese, Indian and Korean companies, for the Asian market.
- Various licensing in/out deals and distributor/agency or supply agreements, with Middle Eastern companies, for the Middle Eastern market.
COMPLIANCE
- Setting up the compliance structure and department Europe/Middle-East/Nord-Africa for a Japanese stock listed multinational.
- Setting up the compliance structure for a Belgian private medtech company.
- Forensic audits into alleged non-compliance and remedying the situation.
- Setting up the export control - sanctions laws compliance for a medtech company.
DATA PRIVACY
- Acting Data Privacy Officer for a Belgian listed pharmaceutical company and a Belgian private medtech company.
- Implementation of GDPR in Belgium/Luxembourg for a German listed medtech company.
- Program manager GDPR implementation worldwide for a Belgian listed health & wellness company.
IP
- Setting up the IP department of a start-up IVD company, determining the IP strategy of the company and organizing the IP awareness and trainings.
- Setting up the IP strategy, including subsidies & grants (>3.5m in 3 years) as well as resolving or settling several major patent litigations in an EU-wide patent litigation, for the EMEA HQ of a Japanese listed company.
TRAINING
- Healthcare compliance.
- Contracts in the pharma and medtech sector: do's and don't.
- Data privacy.
- IP and subsidies.
CORPORATE
- Insider dealing program for a listed company.
- Corporate governance program for a listed company.
- Affiliate restructuring program of a listed company.
FINANCE
- Issuance of a retail bond, a convertible bond and hybrid bonds (> 1bn Euro).
- Project financing transactions for clinical trials (> 100m USD).
- Divestment of a business unit in a multi-country deal in IMM (> 500m Euro).
- Credit facility issuance (> 1.5bn Euro).
- Loan agreement from an international public institution (> 250m Euro).
- Tender of shares to various investment banks (> 20m Euro).